Viridian Therapeutics Enters Material Definitive Agreement
Ticker: VRDN · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1590750
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
TL;DR
Viridian Therapeutics just signed a big deal, filing an 8-K on 10/21/25.
AI Summary
On October 21, 2025, Viridian Therapeutics, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing indicates a significant new contract or partnership for Viridian Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, obligations, and potential outcomes of the agreement.
Key Numbers
- 001-36483 — Commission File Number (SEC file number for Viridian Therapeutics)
- 47-1187261 — IRS Employer Identification No. (Tax identification number for Viridian Therapeutics)
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Business address city and state
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Viridian Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 21, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 21, 2025.
What were Viridian Therapeutics' former company names?
Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Where is Viridian Therapeutics, Inc. incorporated?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Viridian Therapeutics?
The business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Stats: 1,394 words · 6 min read · ~5 pages · Grade level 14.5 · Accepted 2025-10-22 21:53:00
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $22.00 — Stock"), at a public offering price of $22.00 per share. In addition, the Company gra
- $251.35 m — any from the Offering are approximately $251.35 million, not including any exercise of th
- $70 million — quivalents, short-term investments, the $70 million upfront payment receivable from Kissei
- $55 million — be paid in the fourth quarter 2025, the $55 million upfront payment that we received in con
- $115 million — LP ("DRI") and the additional near-term $115 million in potential milestones anticipated und
- $30 million — er the Purchase and Sale Agreement, the $30 million received by the Company from the term l
Filing Documents
- d27166d8k.htm (8-K) — 34KB
- d27166dex11.htm (EX-1.1) — 250KB
- d27166dex51.htm (EX-5.1) — 7KB
- g27166g1021193231699.jpg (GRAPHIC) — 3KB
- g27166g1022102240780.jpg (GRAPHIC) — 2KB
- 0001193125-25-247410.txt ( ) — 483KB
- vrdn-20251021.xsd (EX-101.SCH) — 3KB
- vrdn-20251021_lab.xml (EX-101.LAB) — 18KB
- vrdn-20251021_pre.xml (EX-101.PRE) — 11KB
- d27166d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern the Company's expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: the anticipated closing of the Offering and the period over which the Company estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements; the impact of a prolonged United States federal government shutdown; the Company's anticipated cash resources and projected cash runway, including the Company's expected timeline for, and anticipated revenue of, sales of veligrotug and VRDN-003, and the anticipated receipt of milestone payments in connection with the Purchase and Sale Agreement with DRI; the Company's partnership with Kissei, including the timing of the Company's receipt of the expected upfront payment; and the Company's expectations related to its use of proceeds from the Offering and its existing cash resources. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: other matters that could affect the sufficiency of existing cash, cash equivalents and short-term i
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 1.1 Underwriting Agreement, by and among the Company and the Representatives, dated as of October 21, 2025 5.1 Opinion of Ropes & Gray LLP 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: October 22, 2025 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director